DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The "Global Cervical Cancer Screening Market & Patients, by Test Type (Pap Smear, HPV DNA, VIA), 19 Countries Analysis & Forecast" report has been added to ResearchAndMarkets.com's offering.

Global Cervical Cancer Screening Market is projected to reach US$ 7 Billion by the year 2024

Cervical cancer affects the lower part of the uterus (womb). Cervical cancer generally occurs in women over 30 years. It is mostly caused by the Human Papillomavirus (HPV) Virus. Cervical cancer is the fourth most common cancer prevailing in women and the seventh in terms of overall cancer incidences. Increasing cervical cancer prevalence rate is one of the key factors that drive the cervical cancer screening market. Rapidly increasing female population, growing incidence of HPV infections and increasing awareness about cervical cancer screening programs are also expected to drive the cervical cancer screening market in the near future. The report provides a complete analysis of Global Cervical Cancer Test Market, Screened Population & Mortality. The report Cervical Cancer Screening Market' has been studied from 3 major viewpoints Cervical Cancer Screening Market:

Pap Smear Tests Market HPV DNA Tests Market VIA Tests Market

Cervical Cancer Test Population:

Pap Smear Test Population HPV DNA Test Population VIA Test Population

Cervical Cancer Mortality Population In this section number of deaths by cervical cancer in all the 19 countries from 2011 to 2017 has been captured.

Key Questions Answered in the Report:

What will be the Cervical Cancer Screening Market by 2024? How many women will be screened for Cervical Cancer in the recent future? Which country has the maximum and least market share in Cervical Cancer Screening Market? What will be the Pap Smear Screening Tests Market by 2024? What will be the HPV DNA Screening Tests Market by 2024? In which Region, Visual Inspection with Acetic Acid (VIA) Screening Tests is growing. How many deaths have occurred due to cervical cancer in each country from 2011 to 2017

For more information about this report visit https://www.researchandmarkets.com/research/ppb9pj/global_cervical?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005571/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diagnostics,Cervical Cancer Drugs ,In Vitro Diagnostics

KEYWORD:

INDUSTRY KEYWORD: WOMEN HEALTH ONCOLOGY PHARMACEUTICAL CONSUMER

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 06:10 AM/DISC: 06/06/2018 06:10 AM

http://www.businesswire.com/news/home/20180606005571/en